Guideline update

ESCAT v2 Makes Resistance Clinically Actionable
ESMO has updated its international framework for molecular actionability and introduced a parallel evidence scale for resistance biomarkers. The change reflects a simple reality: sequencing reports need to communicate not only what may work, but what the evidence says probably will not.

Lifelong exercise protects the heart. It can also make the heart harder to read

A New Global Heart Attack Definition Targets a Diagnostic Blind Spot in Women

Cardiac rehabilitation is now explicitly personalised in Europe. Reimbursement could decide who gets it

WHO Rewrote the Typhoid Playbook

Pancreatic Cancer Gets a New Radiation Rulebook

Why some “resistant” hypertension isn’t resistant at all, and what cardiology might be missing

Treating hypertension in pregnancy is possible. Making it routine care is the policy challenge

New global heart failure definition exposes a policy gap: systems still diagnose too late and treat too narrowly

Sugar substitutes were sold as metabolic shortcuts. The evidence is getting harder to ignore
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
